Business Context and Reporting Period
This Form 8-K, filed on January 10, 2025, by Salarius Pharmaceuticals, Inc. (the "Company"), announces the execution of a definitive Merger Agreement with Decoy Therapeutics Inc. ("Decoy"). The transaction is structured as a stock-for-stock merger where Decoy will become a wholly-owned subsidiary of Salarius. The filing also details the cancellation of a warrant held by an accredited investor for $350,000. The report provides extensive disclosure regarding Decoy's business, financial condition, and pipeline, as the combined entity will be driven by Decoy's operations.
Key Financial Metrics
Salarius Pharmaceuticals (Parent):
- Cash Position: As of September 30, 2024, cash and cash equivalents totaled $3.3 million.
- Accumulated Deficit: $80.5 million as of September 30, 2024.
- Net Loss: $4.1 million for the nine months ended September 30, 2024.
- Liquidity: Management believes existing resources are sufficient only into the first half of 2025 absent the Merger.
Decoy Therapeutics (Target):
- Cash Position: Approximately $3.2 million as of September 30, 2024.
- Accumulated Deficit: Approximately $18.3 million as of September 30, 2024.
- Net Loss: Approximately $3.3 million for the nine months ended September 30, 2024.
- Operating Cash Flow: Negative $1.6 million for the nine months ended September 30, 2024.
- Revenue: Decoy has never generated revenue from product sales; all candidates are preclinical.
- Debt: Decoy has outstanding convertible notes and related warrant liabilities subject to fair value adjustments.
Material Changes and Transaction Terms
Merger Structure and Ownership:
- The transaction is a reverse merger where Decoy stockholders will own approximately 85.9% of the combined company on an as-converted-to-common basis, while legacy Salarius stockholders will retain approximately 14.1%.
- Consideration includes Salarius Common Stock (up to 19.9% of outstanding shares) and newly designated Series A Preferred Stock (convertible 1-for-1,000 into Common Stock).
- The exchange ratio is adjustable based on the cash balances of both companies at closing.
Conditions to Closing:
- Qualified Financing: The closing is conditioned on Salarius consummating a financing raising at least $6.0 million in gross proceeds.
- Stockholder Approval: A special meeting will be held to approve the conversion of Series A Preferred Stock and other matters.
- Nasdaq Listing: Continued listing of Salarius Common Stock on Nasdaq is required.
Warrant Cancellation: Salarius paid $350,000 to cancel a warrant to purchase 454,546 shares of common stock.
Outlook, Risks, and Management Commentary
Strategic Outlook:
The combined company intends to leverage Decoy's proprietary IMP 3 ACT platform (Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology) to develop peptide conjugates for infectious diseases and oncology. Key programs include:
- COV: A pan-Coronavirus prophylactic for immunocompromised patients (IND filing expected H1 2026).
- TRI: A broad respiratory antiviral targeting Flu, COVID, and RSV.
- cGPCR: GPCR-targeted conjugates for colorectal cancer.
- P-TAC: Exploratory peptide-based PROTACs utilizing Salarius's SP-3164 compound.
Material Risks:
- Going Concern: Both Salarius and Decoy have substantial doubt regarding their ability to continue as going concerns without the Merger and the Qualified Financing. Salarius has only two full-time employees; Decoy has eight.
- Financing Failure: If the $6.0 million Qualified Financing is not secured, the Merger will not close, potentially leading to Salarius's dissolution or liquidation.
- Dilution: The Qualified Financing and the issuance of shares to Decoy stockholders will result in significant dilution to existing Salarius stockholders.
- Regulatory and Development Risk: All product candidates are preclinical. There is no guarantee of regulatory approval or commercial success.
- Delisting Risk: Salarius faces potential delisting from Nasdaq if it fails to maintain stockholders' equity requirements or is deemed a "public shell."
Investor Verification Checklist
- Verify the status and terms of the proposed $6.0 million Qualified Financing, which is a strict condition precedent to the Merger.
- Confirm Salarius's current cash runway and the specific timeline for the Qualified Financing to ensure it occurs before cash exhaustion.
- Review the pro forma capitalization to understand the exact dilution impact on legacy Salarius shareholders post-financing and post-merger.
- Assess the preclinical data for Decoy's lead programs (COV and TRI) and the timeline for the planned IND filing in H1 2026.
- Monitor Salarius's compliance with Nasdaq listing requirements, specifically the Stockholders' Equity Requirement, given its current financial position.
- Examine the terms of the Series A Preferred Stock and the Beneficial Ownership Limitation (4.99% cap) regarding the conversion to common stock.